TIDMDEST

RNS Number : 1101N

Destiny Pharma PLC

27 September 2021

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director Dealing

Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, announces that it was notified on 27 September 2021 that on that same day, Nick Rodgers, Chairman of the Company, purchased 2,100 Ordinary Shares at a price of 119.7999p per Ordinary Share. Following the transaction his total beneficial interest is 56,073 Ordinary Shares, representing 0.09% of the total issued share capital of the Company.

The above purchase of shares is pursuant to the award of a 2020 bonus to Mr. Rodgers, payable in Destiny Pharma shares (on a net of tax basis). The bonus is payable in two equal tranches following the announcement of the Company' 2020 annual results and 2021 interim results.

Details of the full notification received by the Company are set out below:

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Nick Rodgers 
     -------------------------------  ---------------------------------- 
 2.   Reason for the Notification 
     ------------------------------------------------------------------- 
 a)   Position/status                  Chairman 
     -------------------------------  ---------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  ---------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------- 
 a)   Name                             Destiny Pharma plc 
     -------------------------------  ---------------------------------- 
 b)   LEI                              213800O9WH9Z38EHAC95 
     -------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of the               Ordinary Shares of 1 pence each 
       Financial instrument,            in Destiny Pharma Plc 
       type of instrument 
      Identification code              DEST GB00BDHSP575 
     -------------------------------  ---------------------------------- 
 b)   Nature of the transaction        Purchase of Ordinary Shares 
     -------------------------------  ---------------------------------- 
 c)   Price(s) and volume(s)           119.7999 pence per Ordinary Share 
                                        2,100 Ordinary Shares 
     -------------------------------  ---------------------------------- 
 d)   Aggregated information: 
       Aggregated volume                 See 4c) above 
       Price 
     -------------------------------  ---------------------------------- 
 e)   Date of the transaction          27 September 2021 
     -------------------------------  ---------------------------------- 
 f)   Place of the transaction         London Stock Exchange, AIM Market 
     -------------------------------  ---------------------------------- 
 

Enquiries:

 
                                                    +44 (0) 1273 704 
  Destiny Pharma plc                                 440 
  Neil Clark (Chief Executive Officer) 
   Shaun Claydon (Chief Financial Officer and 
   Company Secretary) 
  finnCap Limited - Nominated Adviser and Joint 
   Broker                                           +44 (0) 20 7220 0500 
  Geoff Nash / Kate Bannatyne / Charlie Beeson 
   (Corporate Finance) 
   Alice Lane (ECM) 
  WG Partners LLP - Joint Broker                    +44 (0) 20 3705 9330 
  Nigel Barnes / Claes Spång / Nigel Birks 
  Optimum Strategic Communications                  +44 (0) 203 174 1789 
  Mary Clark / Hollie Vile / Manel Mateus 
  MC Services AG 
  Anne Hennecke / Andreas Burckhardt                +49-211-529252-0 
 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit https://www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFLSADIDFIL

(END) Dow Jones Newswires

September 27, 2021 10:18 ET (14:18 GMT)

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Destiny Pharma.
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Destiny Pharma.